SCHEMBL1450281

SCHEMBL1450281

OCCN1[CH]CCc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
USP2 O75604 1/20 0.43
CDK4 P11802 1/20 0.43
ALOX15 P16050 1/20 0.43
CCND1 P24385 1/20 0.43
HTR2A P28223 3/20 0.39
MAPT P10636 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 1/20 0.38
MITF O75030 1/20 0.38
RAB9A P51151 1/20 0.38
TSHR P16473 1/20 0.38
SIGMAR1 Q99720 2/20 0.37
LMNA P02545 3/20 0.36
CYP3A4 P08684 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6197328 0.82 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL1450327 0.78 LMNA (0.58) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL2157866 0.78 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL6197010 0.77 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL6637686 0.73 HTR2A (0.61) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL3373922 0.71 MEN1 (0.35) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL8935519 0.71 SIGMAR1 (0.42) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL1450910 0.71 MEN1 (0.45) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL3131072 0.70 ALDH1A1 (0.78) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL14277003 0.70 POLB (0.61) POLBCHRM2CHRM1DRD2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383839-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-02-26 US disclosed
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-05-12 US disclosed
US-7910751-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 US disclosed
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative MOCHIDA PHARMACEUTICAL CO.,LTD (JP) 2008-11-20 US disclosed
EP-1908753-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative TRPV1, TRPV3, TRPA1 ALDH1A1 2362/4885MEN1 4073/4885KMT2A 3094/4885
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE TRPV1, TRPV3, TRPA1 ALDH1A1 2362/4885MEN1 4073/4885KMT2A 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.